Laboratory Dr. Deppe GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laboratory Dr. Deppe GmbH - overview
Established
1980
Location
Kempen, -, Germany
Primary Industry
Consumer Products
About
Based in Germany, Dr. Deppe Group specializes in manufacturing disinfectants and hygiene products, providing essential solutions for healthcare and other industries to meet stringent hygiene standards. Dr. Deppe Group, founded in 1980 and headquartered in Kempen, Germany, focuses on producing disinfectants and hygiene products.
The company has maintained its core operations and does not have any known subsidiaries. The leadership is under the guidance of CEOs Hendrik Hahn and Mark Derks. In July 2024, Adeleon Family Holding acquired Laboratory Dr. Deppe GmbH from Invision, though financial details were not disclosed.
The company has successfully completed a total of 2 deals, with the most recent one occurring on July 25, 2024. Dr. Deppe Group specializes in manufacturing disinfectants and hygiene products tailored for healthcare settings, including hospitals and nursing facilities. Their offerings include high-quality liquid disinfectants, hand sanitizers, soaps, creams, gels, and pre-soaked wipes, all produced in Germany.
The primary customers are professional users in the medical sector, along with businesses in the hospitality and event management industries, ensuring a comprehensive reach across Europe and expanding internationally. In the most recent year of 2022, Dr. Deppe Group reported an EBITDA of EUR 4,165,980. The company's revenue model is centered around B2B transactions, targeting healthcare providers, pharmacies, and clinics that require dependable hygiene solutions.
They offer bulk orders and flexible delivery schedules, emphasizing the quality of their flagship products, such as certified hand sanitizers and disinfectant wipes, which are vital for infection control. The Dr. Deppe Group is focused on developing new products designed to enhance hygiene and safety solutions, although specific release dates are not disclosed. The company plans to expand its market presence into additional European regions and other international markets by leveraging the recent acquisition to increase operational capacity.
The funding from the acquisition, finalized on July 25, 2024, will support these initiatives, allowing Dr. Deppe to enhance its product line and market reach.
Current Investors
Invision
Primary Industry
Consumer Products
Sub Industries
Beauty & Hygiene
Website
www.drdeppe.de
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Laboratory Dr. Deppe GmbH - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Laboratory Dr. Deppe GmbH | - | ||||||||
| Growth | Completed | Laboratory Dr. Deppe GmbH | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.